Clinical outcomes of metastasic melanoma patients treated with ipilimumab and nivolumab: A single institution experience

Autor: D.S. Pesántez Coronel, Aurelio Rodríguez, C.M. Vila, A.M. Arance Fernandez, F. Aya Moreno, H.K. Oberoi Oberoi, M.C. Font Puig

Publikováno v: Annals of Oncology. 30:xi31-xi32

Background Immune checkpoint combination therapy with nivolumab and Ipilimumab for untreated metastatic melanoma has shown higher rates of response rates, progression free survival and overall survival compared to monotherapy (Long et al. ESMO 2019),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f47161e1f866fbbe3add2b6cbbc950fc
https://doi.org/10.1093/annonc/mdz449.041

Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma.

Autor: Martínez-Vila C; Medical Oncology Department, Hospital Clinic.; Medical Oncology Department, Hospital Althaia, Manresa, Spain., Laguna JC; Medical Oncology Department, Hospital Clinic., Segui E; Medical Oncology Department, Hospital Clinic., Ruiz G; Medical Oncology Department, Hospital Clinic., Aya Moreno F; Medical Oncology Department, Hospital Clinic., Fernandez-Morales LM; Medical Oncology Department, Hospital Parc Taulí, Sabadell, Sabadell, Barcelona., Giner Joaquim J; Medical Oncology Department, Hospital Parc Taulí, Sabadell, Sabadell, Barcelona., Padrosa J; Medical Oncology Department, Hospital Clinic., Fernandez L; Medical Oncology Department, Hospital Clinic., Gaba L; Medical Oncology Department, Hospital Clinic., Victoria I; Medical Oncology Department, Hospital Clinic., Arance Fernandez AM; Medical Oncology Department, Hospital Clinic.

Publikováno v: Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2021 Jun 01; Vol. 44 (5), pp. 204-207.